Do analysts rate ADVB or IDN?

Intellicheck has a consensus price target of $6.50, indicating a potential upside of 134.66%. Given Intellicheck's stronger consensus rating and higher probable upside, analysts plainly believe Intellicheck is more favorable than Advanced Biomed. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Advanced Biomed 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Intellicheck 0 Sell rating(s) 3 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50

Do analysts prefer STEM or ADVB?

Stem presently has a consensus target price of $7.45, indicating a potential upside of 30.24%. Given Stem's stronger consensus rating and higher possible upside, research analysts plainly believe Stem is more favorable than Advanced Biomed. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Stem 1 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.80 Advanced Biomed 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation & earnings, STEM or ADVB?

Stem has higher revenue and earnings than Advanced Biomed. Stem is trading at a lower price-to-earnings ratio than Advanced Biomed, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Stem $156.27M 0.35 $137.76M -$8.49 N/A Advanced Biomed N/A N/A -$3.26M $4.82 1.96

Is STEM or ADVB more profitable?

Advanced Biomed has a net margin of 0.00% compared to Stem's net margin of -49.37%. Advanced Biomed's return on equity of 87.74% beat Stem's return on equity. Company Net Margins Return on Equity Return on Assets Stem -49.37% N/A -21.85% Advanced Biomed N/A 87.74% 64.49%

Do analysts recommend ADVB or VHC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Advanced Biomed 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Virnetx 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is ADVB or VHC more profitable?

Advanced Biomed's return on equity of 87.74% beat Virnetx's return on equity. Company Net Margins Return on Equity Return on Assets Advanced Biomed N/A 87.74% 64.49% Virnetx N/A -92.46% -66.74%

Do analysts prefer NTWK or ADVB?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NetSol Technologies 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Advanced Biomed 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts prefer YHNA or ADVB?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score YHN Acquisition I 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Advanced Biomed 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings & valuation, YHNA or ADVB?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio YHN Acquisition I N/A N/A N/A N/A N/A Advanced Biomed N/A N/A -$3.26M $4.82 1.96

Is YHNA or ADVB more profitable?

Advanced Biomed's return on equity of 87.74% beat YHN Acquisition I's return on equity. Company Net Margins Return on Equity Return on Assets YHN Acquisition I N/A N/A N/A Advanced Biomed N/A 87.74% 64.49%

Advanced Biomed (ADVB) Competitors

$9.45 -0.25 (-2.58%)

As of 04:00 PM Eastern

Compare

ADVB vs. IDN, STEM, VHC, NTWK, and YHNA

Should you buy Advanced Biomed stock or one of its competitors? Advanced Biomed's main competitors and comparable companies include Intellicheck (IDN), Stem (STEM), Virnetx (VHC), NetSol Technologies (NTWK), and YHN Acquisition I (YHNA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "application software" industry.

How does Advanced Biomed compare to Intellicheck?

Advanced Biomed (NASDAQ:ADVB) and Intellicheck (NASDAQ:IDN) are both small-cap technology companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, analyst recommendations, earnings, profitability, media sentiment, institutional ownership and valuation.

In the previous week, Advanced Biomed had 1 more articles in the media than Intellicheck. MarketBeat recorded 2 mentions for Advanced Biomed and 1 mentions for Intellicheck. Intellicheck's average media sentiment score of 1.89 beat Advanced Biomed's score of 1.45 indicating that Intellicheck is being referred to more favorably in the news media.

Company	Overall Sentiment
Advanced Biomed	Positive
Intellicheck	Very Positive

42.8% of Intellicheck shares are owned by institutional investors. 27.0% of Advanced Biomed shares are owned by company insiders. Comparatively, 7.8% of Intellicheck shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Intellicheck has a consensus price target of $6.50, indicating a potential upside of 134.66%. Given Intellicheck's stronger consensus rating and higher probable upside, analysts plainly believe Intellicheck is more favorable than Advanced Biomed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Advanced Biomed	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Intellicheck	0 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Intellicheck has higher revenue and earnings than Advanced Biomed. Advanced Biomed is trading at a lower price-to-earnings ratio than Intellicheck, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Advanced Biomed	N/A	N/A	-$3.26M	$4.82	1.96
Intellicheck	$24.11M	2.33	$1.27M	$0.15	18.47

Advanced Biomed has a beta of -0.41, suggesting that its stock price is 141% less volatile than the broader market. Comparatively, Intellicheck has a beta of 0.81, suggesting that its stock price is 19% less volatile than the broader market.

Intellicheck has a net margin of 13.03% compared to Advanced Biomed's net margin of 0.00%. Advanced Biomed's return on equity of 87.74% beat Intellicheck's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Advanced Biomed	N/A	87.74%	64.49%
Intellicheck	13.03%	15.02%	12.27%

Summary

Intellicheck beats Advanced Biomed on 10 of the 15 factors compared between the two stocks.

How does Advanced Biomed compare to Stem?

Stem (NYSE:STEM) and Advanced Biomed (NASDAQ:ADVB) are both small-cap technology companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, risk, media sentiment, earnings and valuation.

Stem presently has a consensus target price of $7.45, indicating a potential upside of 30.24%. Given Stem's stronger consensus rating and higher possible upside, research analysts plainly believe Stem is more favorable than Advanced Biomed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Stem	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80
Advanced Biomed	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

61.6% of Stem shares are owned by institutional investors. 5.1% of Stem shares are owned by insiders. Comparatively, 27.0% of Advanced Biomed shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Stem had 15 more articles in the media than Advanced Biomed. MarketBeat recorded 17 mentions for Stem and 2 mentions for Advanced Biomed. Advanced Biomed's average media sentiment score of 1.45 beat Stem's score of 0.33 indicating that Advanced Biomed is being referred to more favorably in the news media.

Company	Overall Sentiment
Stem	Neutral
Advanced Biomed	Positive

Stem has higher revenue and earnings than Advanced Biomed. Stem is trading at a lower price-to-earnings ratio than Advanced Biomed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Stem	$156.27M	0.35	$137.76M	-$8.49	N/A
Advanced Biomed	N/A	N/A	-$3.26M	$4.82	1.96

Stem has a beta of 1.5, meaning that its stock price is 50% more volatile than the broader market. Comparatively, Advanced Biomed has a beta of -0.41, meaning that its stock price is 141% less volatile than the broader market.

Advanced Biomed has a net margin of 0.00% compared to Stem's net margin of -49.37%. Advanced Biomed's return on equity of 87.74% beat Stem's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Stem	-49.37%	N/A	-21.85%
Advanced Biomed	N/A	87.74%	64.49%

Summary

Stem and Advanced Biomed tied by winning 7 of the 14 factors compared between the two stocks.

How does Advanced Biomed compare to Virnetx?

Advanced Biomed (NASDAQ:ADVB) and Virnetx (NASDAQ:VHC) are both small-cap technology companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, earnings, media sentiment, risk, institutional ownership, valuation and profitability.

Advanced Biomed has a beta of -0.41, meaning that its share price is 141% less volatile than the broader market. Comparatively, Virnetx has a beta of 2.3, meaning that its share price is 130% more volatile than the broader market.

In the previous week, Advanced Biomed had 1 more articles in the media than Virnetx. MarketBeat recorded 2 mentions for Advanced Biomed and 1 mentions for Virnetx. Virnetx's average media sentiment score of 1.87 beat Advanced Biomed's score of 1.45 indicating that Virnetx is being referred to more favorably in the news media.

Company	Overall Sentiment
Advanced Biomed	Positive
Virnetx	Very Positive

Advanced Biomed has higher earnings, but lower revenue than Virnetx. Virnetx is trading at a lower price-to-earnings ratio than Advanced Biomed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Advanced Biomed	N/A	N/A	-$3.26M	$4.82	1.96
Virnetx	$114K	433.29	-$18.23M	-$5.37	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Advanced Biomed	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Virnetx	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

10.4% of Virnetx shares are held by institutional investors. 27.0% of Advanced Biomed shares are held by insiders. Comparatively, 15.7% of Virnetx shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Advanced Biomed's return on equity of 87.74% beat Virnetx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Advanced Biomed	N/A	87.74%	64.49%
Virnetx	N/A	-92.46%	-66.74%

Summary

Advanced Biomed beats Virnetx on 7 of the 11 factors compared between the two stocks.

How does Advanced Biomed compare to NetSol Technologies?

NetSol Technologies (NASDAQ:NTWK) and Advanced Biomed (NASDAQ:ADVB) are both small-cap technology companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, earnings, media sentiment, profitability, institutional ownership and dividends.

NetSol Technologies has a net margin of 2.49% compared to Advanced Biomed's net margin of 0.00%. Advanced Biomed's return on equity of 87.74% beat NetSol Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NetSol Technologies	2.49%	4.24%	2.76%
Advanced Biomed	N/A	87.74%	64.49%

NetSol Technologies has a beta of 0.93, indicating that its stock price is 7% less volatile than the broader market. Comparatively, Advanced Biomed has a beta of -0.41, indicating that its stock price is 141% less volatile than the broader market.

In the previous week, NetSol Technologies had 3 more articles in the media than Advanced Biomed. MarketBeat recorded 5 mentions for NetSol Technologies and 2 mentions for Advanced Biomed. Advanced Biomed's average media sentiment score of 1.45 beat NetSol Technologies' score of 0.59 indicating that Advanced Biomed is being referred to more favorably in the news media.

Company	Overall Sentiment
NetSol Technologies	Positive
Advanced Biomed	Positive

16.0% of NetSol Technologies shares are held by institutional investors. 13.5% of NetSol Technologies shares are held by company insiders. Comparatively, 27.0% of Advanced Biomed shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

NetSol Technologies has higher revenue and earnings than Advanced Biomed. Advanced Biomed is trading at a lower price-to-earnings ratio than NetSol Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NetSol Technologies	$66.09M	0.73	$2.92M	$0.15	27.00
Advanced Biomed	N/A	N/A	-$3.26M	$4.82	1.96

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NetSol Technologies	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Advanced Biomed	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

NetSol Technologies beats Advanced Biomed on 8 of the 13 factors compared between the two stocks.

How does Advanced Biomed compare to YHN Acquisition I?

YHN Acquisition I (NASDAQ:YHNA) and Advanced Biomed (NASDAQ:ADVB) are both small-cap technology companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, risk, analyst recommendations, profitability, media sentiment, dividends, earnings and valuation.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
YHN Acquisition I	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Advanced Biomed	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Advanced Biomed's return on equity of 87.74% beat YHN Acquisition I's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
YHN Acquisition I	N/A	N/A	N/A
Advanced Biomed	N/A	87.74%	64.49%

YHN Acquisition I has a beta of 0.01, suggesting that its stock price is 99% less volatile than the broader market. Comparatively, Advanced Biomed has a beta of -0.41, suggesting that its stock price is 141% less volatile than the broader market.

In the previous week, YHN Acquisition I and YHN Acquisition I both had 2 articles in the media. Advanced Biomed's average media sentiment score of 1.45 beat YHN Acquisition I's score of 0.94 indicating that Advanced Biomed is being referred to more favorably in the news media.

Company	Overall Sentiment
YHN Acquisition I	Positive
Advanced Biomed	Positive

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
YHN Acquisition I	N/A	N/A	N/A	N/A	N/A
Advanced Biomed	N/A	N/A	-$3.26M	$4.82	1.96

Summary

Advanced Biomed beats YHN Acquisition I on 3 of the 4 factors compared between the two stocks.

Get Advanced Biomed News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ADVB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ADVB vs. The Competition

Export

Metric	Advanced Biomed	Software Industry	Technology Sector	NASDAQ Exchange
Market Cap	$15.59M	$16.28B	$29.64B	$12.85B
Dividend Yield	N/A	3.41%	2.74%	11.27%
P/E Ratio	1.96	140.34	76.21	25.51
Price / Sales	N/A	1,278.53	588.19	123.12
Price / Cash	N/A	46.37	48.04	36.03
Price / Book	2.94	8.70	7.86	6.34
Net Income	-$3.26M	$436.23M	$677.18M	$349.45M
7 Day Performance	17.83%	2.11%	0.88%	-0.10%
1 Month Performance	18.13%	7.21%	4.30%	4.36%
1 Year Performance	N/A	5.35%	187.29%	14.91%

Advanced Biomed Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ADVB Advanced Biomed	1.3614 of 5 stars	$9.45 -2.6%	N/A	N/A	$15.59M	N/A	1.96	40	Positive News Short Interest Decrease
IDN Intellicheck	3.611 of 5 stars	$2.85 -0.3%	$6.50 +128.1%	-47.9%	$57.96M	$22.67M	19.00	50	Positive News
STEM Stem	2.5662 of 5 stars	$5.64 +0.5%	$7.45 +32.1%	-64.0%	$54.01M	$156.27M	N/A	660
VHC Virnetx	0.5961 of 5 stars	$13.19 +3.1%	N/A	N/A	$53.54M	$160K	N/A	20	Positive News High Trading Volume
NTWK NetSol Technologies	1.5432 of 5 stars	$4.05 flat	N/A	+2.0%	$48.10M	$66.09M	27.00	1,460	News Coverage Short Interest Decrease

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ADVB) was last updated on 8/31/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Advanced Biomed (ADVB) Competitors

ADVB vs. IDN, STEM, VHC, NTWK, and YHNA

How does Advanced Biomed compare to Intellicheck?

Summary

How does Advanced Biomed compare to Stem?

Summary

How does Advanced Biomed compare to Virnetx?

Summary

How does Advanced Biomed compare to NetSol Technologies?

Summary

How does Advanced Biomed compare to YHN Acquisition I?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADVB vs. The Competition

Advanced Biomed Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Advanced Biomed (ADVB) Competitors

ADVB vs. IDN, STEM, VHC, NTWK, and YHNA

How does Advanced Biomed compare to Intellicheck?

Does the media favor ADVB or IDN?

Do insiders & institutionals believe in ADVB or IDN?

Do analysts rate ADVB or IDN?

Which has stronger earnings & valuation, ADVB or IDN?

Which has more risk and volatility, ADVB or IDN?

Is ADVB or IDN more profitable?

Summary

How does Advanced Biomed compare to Stem?

Do analysts prefer STEM or ADVB?

Do insiders & institutionals believe in STEM or ADVB?

Does the media refer more to STEM or ADVB?

Which has stronger valuation & earnings, STEM or ADVB?

Which has more risk & volatility, STEM or ADVB?

Is STEM or ADVB more profitable?

Summary

How does Advanced Biomed compare to Virnetx?

Which has more risk and volatility, ADVB or VHC?

Does the media favor ADVB or VHC?

Which has stronger valuation and earnings, ADVB or VHC?

Do analysts recommend ADVB or VHC?

Do institutionals and insiders have more ownership in ADVB or VHC?

Is ADVB or VHC more profitable?

Summary

How does Advanced Biomed compare to NetSol Technologies?

Is NTWK or ADVB more profitable?

Which has more risk and volatility, NTWK or ADVB?

Does the media refer more to NTWK or ADVB?

Do insiders and institutionals have more ownership in NTWK or ADVB?

Which has preferable earnings and valuation, NTWK or ADVB?

Do analysts prefer NTWK or ADVB?

Summary

How does Advanced Biomed compare to YHN Acquisition I?

Do analysts prefer YHNA or ADVB?

Is YHNA or ADVB more profitable?

Which has more volatility & risk, YHNA or ADVB?

Does the media favor YHNA or ADVB?

Which has better earnings & valuation, YHNA or ADVB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADVB vs. The Competition

Advanced Biomed Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools